Frontiers in Oncology (Oct 2020)
Development and External Validation of a Nomogram to Predict Recurrence-Free Survival After R0 Resection for Stage II/III Gastric Cancer: An International Multicenter Study
- Jun Lu,
- Jun Lu,
- Jun Lu,
- Jun Lu,
- Bin-bin Xu,
- Bin-bin Xu,
- Bin-bin Xu,
- Bin-bin Xu,
- Chao-hui Zheng,
- Chao-hui Zheng,
- Chao-hui Zheng,
- Chao-hui Zheng,
- Ping Li,
- Ping Li,
- Ping Li,
- Ping Li,
- Jian-wei Xie,
- Jian-wei Xie,
- Jian-wei Xie,
- Jian-wei Xie,
- Jia-bin Wang,
- Jia-bin Wang,
- Jia-bin Wang,
- Jia-bin Wang,
- Jian-xian Lin,
- Jian-xian Lin,
- Jian-xian Lin,
- Jian-xian Lin,
- Qi-yue Chen,
- Qi-yue Chen,
- Qi-yue Chen,
- Qi-yue Chen,
- Mark J. Truty,
- Chang-ming Huang,
- Chang-ming Huang,
- Chang-ming Huang,
- Chang-ming Huang
Affiliations
- Jun Lu
- Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China
- Jun Lu
- Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China
- Jun Lu
- Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China
- Jun Lu
- Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China
- Bin-bin Xu
- Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China
- Bin-bin Xu
- Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China
- Bin-bin Xu
- Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China
- Bin-bin Xu
- Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China
- Chao-hui Zheng
- Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China
- Chao-hui Zheng
- Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China
- Chao-hui Zheng
- Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China
- Chao-hui Zheng
- Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China
- Ping Li
- Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China
- Ping Li
- Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China
- Ping Li
- Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China
- Ping Li
- Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China
- Jian-wei Xie
- Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China
- Jian-wei Xie
- Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China
- Jian-wei Xie
- Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China
- Jian-wei Xie
- Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China
- Jia-bin Wang
- Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China
- Jia-bin Wang
- Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China
- Jia-bin Wang
- Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China
- Jia-bin Wang
- Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China
- Jian-xian Lin
- Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China
- Jian-xian Lin
- Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China
- Jian-xian Lin
- Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China
- Jian-xian Lin
- Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China
- Qi-yue Chen
- Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China
- Qi-yue Chen
- Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China
- Qi-yue Chen
- Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China
- Qi-yue Chen
- Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China
- Mark J. Truty
- Department of Surgery, Mayo Clinic, Rochester, MN, United States
- Chang-ming Huang
- Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China
- Chang-ming Huang
- Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China
- Chang-ming Huang
- Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China
- Chang-ming Huang
- Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China
- DOI
- https://doi.org/10.3389/fonc.2020.574611
- Journal volume & issue
-
Vol. 10
Abstract
Background: The benefit of adjuvant chemotherapy varies widely among patients with stage II/III gastric cancer (GC), and tools predicting outcomes for this patient subset are lacking. We aimed to develop and validate a nomogram to predict recurrence-free survival (RFS) and the benefits of adjuvant chemotherapy after radical resection in patients with stage II/III GC.Methods: Data on patients with stage II/III GC who underwent R0 resection from January 2010 to August 2014 at Fujian Medical University Union Hospital (FMUUH) (n = 1,240; training cohort) were analyzed by Cox regression to identify independent prognostic factors for RFS. A nomogram including these factors was internally and externally validated in FMUUH (n = 306) and a US cohort (n = 111), respectively.Results: The multivariable analysis identified age, differentiation, tumor size, number of examined lymph nodes, pT stage, pN stage, and adjuvant chemotherapy as associated with RFS. A nomogram including the above 7 factors was significantly more accurate in predicting RFS compared with the 8th AJCC-TNM staging system for patients in the training cohort. The risk of peritoneal metastasis was higher and survival after recurrence was significantly worse among patients calculated by the nomogram to be at high risk than those at low risk. The nomogram's predictive performance was confirmed in both the internal and external validation cohorts.Conclusion: A novel nomogram is available as a web-based tool and accurately predicts long-term RFS for GC after radical resection. The tool can also be used to determine the benefit of adjuvant chemotherapy by comparing scores with and without this intervention.
Keywords